Reflecting on a decade of the international consensus on ANA patterns (ICAP): Accomplishments and challenges from the perspective of the 7th ICAP workshop
- PMID: 39187221
- DOI: 10.1016/j.autrev.2024.103608
Reflecting on a decade of the international consensus on ANA patterns (ICAP): Accomplishments and challenges from the perspective of the 7th ICAP workshop
Abstract
The International Consensus on ANA Patterns (ICAP) is an ongoing international initiative dedicated to harmonizing technical and interpretation aspects of the HEp-2 IFA test. Comprised of internationally recognized experts in autoimmunity and HEp-2 IFA testing, ICAP has operated for the last 10 years by promoting accurate reading, interpretation, and reporting of HEp-2 IFA images by professionals involved in various areas related to autoimmune diseases, such as clinical diagnostic laboratories, academic research, IVD industry, and patient care. ICAP operates through continuous information exchange with the international community and encourages the participation of younger experts from all over the world. The 7th ICAP workshop has addressed several aspects that originated from this interaction with the international community and has effectively established objective goals and tasks to be delivered over the next two years. Some of these are outlined in this article, including the planning of three audio-visual educational modules to be posted at the www.anapattern.org website, the classification of two novel HEp-2 IFA patterns, the implementation of a project dedicated to continuously updating the information on the clinical and immunologic relevance of the HEp-2 IFA patterns, and the launch of two additional branches of the HEp-2 Clinical and Immunological (HEp-2 CIC) project.
Keywords: Anti-cell antibodies; Antinuclear antibodies; Autoantibodies; Autoimmunity laboratory testing; HEp-2 cell indirect immunofluorescence; Systemic autoimmune diseases.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Luis E. C. Andrade reports a relationship with Inova that includes: consulting or advisory. May Choi receives consulting fees from Werfen, MitogenDx, AstraZeneca, GlaxoSmithKline, Celltrion, Organon, and Mallinckrodt Pharmaceuticals. Jan Damoiseaux is consultant for ThermoFisher/Phadia and Werfen/Inova and receives speaker fees from Euroimmun, ThermoFisher/Phadia, Werfen/Inova, and Menarini. Carlos Alberto von Mühlen is consultant for Euroimmun and ARTIVA Biotherapeutics. Marvin J. Fritzler was and/or continues to be a consultant to Inova/Werfen, Alexion Pharmaceuticals, and Bio-Rad. Marvin J. Fritzler and May Choi are directors of Mitogen Diagnostics Corporation. ICAP is partially supported by grants from the American Proficiency Institute, Grifols, Immunoconcepts, Bio-Rad, Aesku Group, Biosystems, Trinity Biotech, Mitogen Diagnostics, A.Menarini Diagnostics, Euroimmun, ThremoFischer Scientific, and Inova Diagnostics. The funding organizations played no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the report for publication. The corresponding author, Luis E. C. Andrade, is a member of the editorial board of Autoimmunity Reviews. Luis Andrade and the other authors declare that they have no other known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
